What is the mechanism of action of DSIP?

Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. For metabolic and glycemic applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Mechanism remains incompletely characterised. The metabolic / endocrine interpretation focuses on the pathway-level detail rather than on any single high-level summary.

How long until I see results from DSIP?

Acute effects from DSIP appear within hours of dosing for receptor-level changes. metabolic and glycemic endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What should I look for in DSIP sourcing and quality?

Acceptable DSIP certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 848 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Is DSIP safe during pregnancy or breastfeeding?

DSIP, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the standard dosing protocol for DSIP?

Conventional DSIP dosing is 100-500 mcg 1x daily before sleep via subq/intranasal. For metabolic and glycemic use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Home/ Compounds/ DSIP

DSIP

Metabolic

For metabolic-syndrome, type-2-diabetes-spectrum, and obesity-medicine indications, DSIP is one component in a multi-layer protocol. Mechanism remains incompletely characterised Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier.. CGM-tracked individual response in the first cycle, paired with adequate protein intake and resistance training, is the practical framework for evaluating whether DSIP contributes meaningfully at the 100-500 mcg 1x daily before sleep dose.

Metabolic / Endocrine Applications

GLP-1 SynergyLiver MetabolismInsulin SensitivityAppetite RegulationWeight Management

Key Takeaways

Metabolic lens: DSIP is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers.
Mechanism: Mechanism remains incompletely characterised.
Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle.
Metabolic dose: 100-500 mcg 1x daily before sleep via subq/intranasal.
Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.

Metabolic / Endocrine Mechanism

Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. The metabolic medicine framework evaluates DSIP against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.

Visceral fat and the cardiometabolic axis

DSIP's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.

Weight management and the appetite circuit

Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.

Insulin signalling and glycemic effect

DSIP's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.

Metabolic / Endocrine Applications

Weight Management

In the metabolic syndrome population, DSIP for weight management produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Gastric Emptying

DSIP for gastric emptying is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Insulin Sensitivity

Where DSIP is used for insulin sensitivity, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

GLP-1 Synergy

In the metabolic syndrome population, DSIP for glp-1 synergy produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-500 mcg	4–6 weeks initial cycle
Metabolic focus	SubQ	100-500 mcg	1x daily before sleep
Maintenance phase	SubQ	70-500 mcg	Ongoing with periodic pauses

Dose timing for DSIP is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.

DSIP + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with DSIP's mechanism in metabolic / endocrine protocols.
DSIP + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with DSIP's mechanism in metabolic / endocrine protocols.
DSIP + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with DSIP's mechanism in metabolic / endocrine protocols.
DSIP + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with DSIP's mechanism in metabolic / endocrine protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small human series

Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants.

Lens-specific safety considerations for metabolic / endocrine use of DSIP: Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

Supporting

DSIP and HPA axis modulation

PMID 20066503

DSIP vs Related Peptides

Compound	Profile	Onset	Best For
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	Metabolic
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding
Cagrilintide	Long-acting amylin analogue	~7 days	A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction

Frequently Asked Questions

Is DSIP appropriate alongside metformin or other diabetes medications?

Most peptide compounds are compatible with metformin and complementary to sulfonylurea or insulin therapy with appropriate dose adjustment. Users on sulfonylureas or insulin should have those doses re-evaluated when adding DSIP to avoid hypoglycaemia. Metformin combinations are generally well-tolerated and frequently used in metabolic medicine clinics.

Will DSIP affect my muscle mass during weight loss?

Aggressive weight loss without adequate protein intake and resistance training results in significant lean-mass loss with most metabolic compounds, including DSIP. Pairing the metabolic protocol with 1.6–2.0 g/kg/day protein and twice-weekly resistance training preserves lean mass during the cut. This is now standard of care in metabolic medicine clinics.

Will I regain weight after stopping DSIP?

For most compounds in this class, partial weight regain after discontinuation is the typical pattern unless dietary and activity inputs have been fundamentally changed during the cycle. Metabolic-medicine practice increasingly frames peptide therapy as chronic rather than time-limited for weight management indications.

Pancreatitis or thyroid risk?

Where DSIP engages the GLP-1 or GIP pathway, pancreatitis is a rare but serious adverse event warranting vigilance for severe persistent abdominal pain. Medullary thyroid carcinoma and MEN-2 syndrome are formal contraindications for GLP-1-class compounds based on rodent C-cell hyperplasia findings. Other compound classes do not carry these specific concerns.

What are the safety considerations for DSIP?

Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. For metabolic and glycemic use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. DSIP's ~7 min plasma; CNS effects longer pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

What route should I use for DSIP?

DSIP is delivered by subq/intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Clinical Protocol

Start a DSIP Protocol

Alukard provides physician-supervised metabolic protocols with GMP-certified DSIP and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: ~7 min plasma; CNS effects longer
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small human series

Stack Partners

Semaglutide (GLP-1)

Cagrilintide

MOTS-c

Tesamorelin

AOD-9604

Research Note

All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised metabolic protocols

Start Your Metabolic / Endocrine Protocol for DSIP

Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised